C

Coherus BioSciences
D

CHRS

1.08000
USD
-0.03
(-2.26%)
مغلق
حجم التداول
59,648
الربح لكل سهم
-1
العائد الربحي
-
P/E
-12
حجم السوق
125,161,401
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    K
    KRYS
    5.170
    (2.83%)
    188.030 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    R
    RGNX
    -0.08500
    (-1.15%)
    7.28000 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Coherus BioSciences

القطاع: Healthcare
الصناعة: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.